Roberto Alonzi1, Peter J. Hoskin1,
N Jane Taylor2, Quan S. Ng1, Henry Mandeville1,
Uma Patel1, J James Stirling2, James A. d'Arcy3,
David J. Collins3, Martin O. Leach3, Anwar R. Padhani2
1Marie Curie Research Wing, Mount
Vernon Cancer Centre, Northwood, London, United Kingdom; 2Paul
Strickland Scanner Centre, Mount Vernon Cancer Centre, Northwood, London,
United Kingdom; 3CRUK-EPSRC Cancer Imaging Centre, Institute of
Cancer Research & Royal Marsden Hospital, Sutton, Surrey, United Kingdom
Radiotherapy
may be delivered in combination with vascular targeting agents. The
performance of imaging biomarkers for response assessment may be compromised
by the differing or conflicting effects between drug and radiation on tumor
tissues. Previous studies have shown that DCE-MRI only partially describes
the vascular changes in this setting. This study has evaluated the ability
for Intrinsic Susceptibility-Weighted MRI to assess the response of
Combretastatin-A4-Phosphate during radiotherapy for prostate cancer. We
conclude that R2* has the potential to be an alternative, clinically useable,
response biomarker for assessment of vascular disruptive therapy in
combination with radiotherapy in prostate cancer.